Cambium BioASX:CMB -6.74%34 FCF Yield % is -32.08 as of Jun. 26, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,418 Biotechnology companies, Cambium Bio ranks worse than 75.88% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cambium Bio FCF Yield % Related Terms
Cambium Bio FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cambium Bio's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Cambium Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cambium Bio's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a FCF Yield % of -32.08 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #1076 out of 1418 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Cambium Bio's FCF Yield % too high?
Cambium Bio's current FCF Yield % is -32.08. Based on the distribution chart, Cambium Bio ranks #1076 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #1076 out of 1418 companies for FCF Yield %. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cambium Bio and its competitors. Cambium Bio's current FCF Yield % is -32.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current FCF Yield % of -32.08. The current FCF Yield % is -32.08. Cambium Bio's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current FCF Yield % is -32.08 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score
Get the complete analysis for ASX:CMB
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
